Mark Stejbach
Directeur/Membre du Conseil chez INDIVIOR PLC
Fortune : 238 953 $ au 30/04/2024
Postes actifs de Mark Stejbach
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| INDIVIOR PLC | Directeur/Membre du Conseil | 24/03/2021 | - |
| Independent Dir/Board Member | 24/03/2021 | - |
Historique de carrière de Mark Stejbach
Anciens postes connus de Mark Stejbach
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| FLEXION THERAPEUTICS, INC. | Directeur/Membre du Conseil | 13/09/2016 | 19/11/2021 |
| Independent Dir/Board Member | 13/09/2016 | 19/11/2021 | |
| ALKERMES PLC | Corporate Officer/Principal | 05/03/2012 | 01/10/2018 |
| TENGION, INC. | Public Communications Contact | 21/10/2010 | 01/01/2012 |
| Corporate Officer/Principal | 19/01/2010 | 01/07/2011 | |
| Sales & Marketing | 01/08/2008 | 19/01/2010 | |
Commonwealth National Fund, Inc.
 Commonwealth National Fund, Inc. Financial ConglomeratesFinance Commonwealth National Fund, Inc. functions as an investment fund. The private company is based in Stuart. | Directeur/Membre du Conseil | 01/01/2003 | 01/01/2011 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01/01/1987 | 01/07/2008 |
Biogen MA, Inc.
 Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/01/1997 | 01/01/1997 |
Formation de Mark Stejbach
| Virginia Polytechnic Institute & State University | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Statistiques
Internationale
| Etats-Unis | 9 |
| Irlande | 2 |
Opérationnelle
| Corporate Officer/Principal | 4 |
| Director/Board Member | 3 |
| Independent Dir/Board Member | 2 |
Sectorielle
| Health Technology | 7 |
| Consumer Services | 3 |
| Finance | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| TENGION, INC. | Health Technology |
| MERCK & CO., INC. | Health Technology |
| ALKERMES PLC | Health Technology |
| INDIVIOR PLC | Health Technology |
| Entreprise privées | 3 |
|---|---|
Biogen MA, Inc.
Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Health Technology |
Flexion Therapeutics, Inc.
 Flexion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA. | Health Technology |
Commonwealth National Fund, Inc.
Commonwealth National Fund, Inc. Financial ConglomeratesFinance Commonwealth National Fund, Inc. functions as an investment fund. The private company is based in Stuart. | Finance |
- Bourse
- Insiders
- Mark Stejbach
- Expérience